Top line results expected in Q4 2023 for our phase 3 OnTarget trial of crofelemer for preventative treatment of cancer therapy‑related diarrhea.

We are supporting investigator-initiated proof-of-concept studies of crofelemer for the rare disease indications of short bowel syndrome and microvillus inclusion disease in the US, EU, and Middle East/North Africa regions, with results expected before the end of 2023 and in 2024.

We are dedicated to supporting sustainability and local communities as we develop first-in-class, plant-based prescription medicines to address unmet medical needs for people globally.

Our product portfolio addresses multiple indications for gastrointestinal (GI) diseases, spanning multiple stages of development from preclinical to commercial approval.